Does N-Acetylcysteine (Parvolex) prophylaxis reduce the incidence of renal impairment after on pump Coronary artery bypass surgery? A prospective randomised controlled trial.
Phase 1
- Conditions
- Renal impairment after coronary artery byapass surgeryMedDRA version: 9.1Level: LLTClassification code 10006894Term: CABG
- Registration Number
- EUCTR2006-006815-62-GB
- Lead Sponsor
- niversity Hospitals of South Manchester NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 224
Inclusion Criteria
Patients undergoing elective coronary artery bypasssurgery at Wythenshawe Hospital Manchester
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Urgent and emergency cases
Patients with history of hypersensitivity to N-Acetylcysteine
Patients already taking N-Acetylcysteine
Patients with existing renal failure (creatinine more than 120mmol/l –upper limit of normal range in our laboratory
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method